Roboterassistierte Prostatabiopsie mit einer neuartigen Ultraschallsonde
Robotergestützte Prostata-Biopsie mit einer neuartigen Ultraschallsonde
Prostate cancer (PCa) is the most diagnosed type of cancer and the second leading cause of cancer related deaths among US men, and its incidence has increased steadily in the last decade. Efforts to address the rise in PCa diagnosis without overdetection and overtreatment include targeted biopsy techniques for clinically significant PCa using magnetic resonance imaging (MRI), and precision targeted biopsy guided by ultrasound and fused to the MRI.
The study aims to improve prostate biopsy with a novel ultrasound probe and robot developed at Johns Hopkins, the ProBot device. The trial is a Phase 1 clinical trial to evaluate the safety and feasibility of the new device.
ProBot is an entirely new concept including a novel ultrasound probe and robot kinematics specifically designed for the prostate. It operates with only two degrees of freedom configured such that the motions for 3D image scanning and biopsy may not deform the prostate gland, thus improving the accuracy of MRI-ultrasound fusion and needle targeting at biopsy.
ProBot is a small and lightweight robot (1.3Kg including the ultrasound probe). It allows hands-free operation of its ultrasound probe at 3D image scanning and needle targeting supervised by the urologist.
In addition to MRI-targeted biopsy (TB), at systematic biopsy (SB), instead of using the common template plan that is the same for all patients, the innovative software optimizes the plan for each patient to obtain a diagnosis that is representative of the whole gland histology. The ProBot robot is also uniquely capable of transrectal (TR) and transperineal (TP) biopsy.
The aims of the study are to determine the safety and feasibility of the new device at TR and TP biopsies.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Rana Harb
- Telefonnummer: 410-502-5500
- E-Mail: rharb1@jhmi.edu
Studieren Sie die Kontaktsicherung
- Name: Sara A Naizghi
- Telefonnummer: 720-965-9494 4105501980
- E-Mail: snaizgh1@jh.edu
Studienorte
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Rekrutierung
- Johns Hopkins Hospital
-
Kontakt:
- Rana Harb
- Telefonnummer: 410-502-5500
- E-Mail: rharb1@jhmi.edu
-
Kontakt:
- Sara A Naizghi
- Telefonnummer: 720-965-9494
- E-Mail: snaizgh1@jh.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Included in the study will be:
-
Men between the ages of 40 and 75
-
Men must have one of the following "high risk" features:
- PSA > 4.0 ng/ml and/or abnormal digital rectal examination (DRE)
- ASAP (atypical small acinar proliferation) on previous biopsy
-
Men with mpMRI or bpMRI exams, including both PI-RADS ≤2 and PI-RADS ≥3.
Excluded from the study will be patients without available mpMRI exams and patients:
-
Females and children because of the prostate cancer targeted disease.
-
Patients who are not recommended or in whom TR or TP prostate biopsy is considered high-risk:
- Patients with previous rectal surgery.
- Patients with anal stenosis or coagulopathy.
- Patients on active anticoagulation medication (eg. Coumadin, Lovenox, or Heparin).
- Patients who cannot tolerate periprostatic Lidocaine block anesthesia or in whom anesthesia is considered high-risk.
-
Patients who already had a prostate biopsy taken with the ProBot investigational device.
-
Vulnerable populations, such as prisoners, institutionalized individuals.
-
Patients who are unwilling or unable to sign informed consent (no assent required).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Machbarkeit des Geräts
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Transrectal biopsy (TR)
Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transrectal path |
Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot |
|
Experimental: Transperineal biopsy (TP)
Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transperineal path. |
Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Device feasibility as assessed by patient discomfort score
Zeitfenster: Immediately after the procedure
|
Scale 1-10, 10 highest discomfort |
Immediately after the procedure
|
|
Device feasibility as assessed by maximal procedural pain
Zeitfenster: Immediately after the procedure
|
Scale 1-10, 10 highest pain |
Immediately after the procedure
|
|
Device feasibility as assessed by the rate of complications
Zeitfenster: Throughout the study, each case recorded within 1 month of the procedure
|
Rate of complications |
Throughout the study, each case recorded within 1 month of the procedure
|
|
Device feasibility as assessed by serious adverse events
Zeitfenster: Up to 1 month post procedure
|
Serious Adverse events throughout the study |
Up to 1 month post procedure
|
|
Device feasibility as assessed by the rate of successful completion of cases
Zeitfenster: Immediately post procedure
|
Rate of cases completed successfully throughout the study |
Immediately post procedure
|
|
Device feasibility as assessed by the procedure time
Zeitfenster: Immediately post procedure
|
Times of the procedures measured in minutes throughout the study |
Immediately post procedure
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Prostate cancer detection rates at targeted biopsy (TB)
Zeitfenster: Up to 1 month post procedure
|
Clinically significant PCa detection rates at TB throughout the study |
Up to 1 month post procedure
|
|
Prostate cancer detection rates at systematic biopsy (SB)
Zeitfenster: Up to one month post procedure
|
Clinically significant PCa detection rates at SB throughout the study |
Up to one month post procedure
|
|
Needle targeting errors
Zeitfenster: Immediately post procedure
|
Measured in ultrasound throughout the study |
Immediately post procedure
|
|
Prostate deformations (mm)
Zeitfenster: Immediately post procedure
|
Maximum deformation of the gland between the start and end of the procedure measured in [mm] throughout the study |
Immediately post procedure
|
|
Prostate displacement (mm)
Zeitfenster: Immediately post procedure
|
Displacement of the gland between the start and end of the procedure measured in [mm] throughout the study |
Immediately post procedure
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Misop Han, MD, Johns Hopkins University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Pathologische Prozesse
- Genitale Neubildungen, männlich
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Genitalerkrankungen, männlich
- Prostataerkrankungen
- Männliche Urogenitalerkrankungen
- Pathologische Zustände, Anzeichen und Symptome
- Prostataneoplasmen
- Erkrankung
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- IRB00229568
- R01CA303859 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .